PPG to Predict Ejection Fraction and Other Echographic Data in the General Population
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-120
SponsorTulane University
About this trial
The investigators are aiming to investigate the association between ejection fraction (EF) determined by echocardiography and signals obtained from Photoplethysmography (PPG) in the general population. The investigators are also aiming to investigate the association between blood pressure and signals obtained from PPG in the general population.
Finally, the investigators are also aiming to investigate the association between signals obtained from PPG in the general population to cardioechographic findings such as, valvular heart disease, structural heart diseases, cardiomyopathies, pericardial disease etc.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Male or Female aged18 years or older.
Patients scheduled to undergo an echocardiogram at Tulane Medical Center.
Disqualifiers
Participants under 18 years of age.
Participants with cognitive impairments.
Participants with a physical inability to wear the Biostrap during the echocardiogram.
Individuals who cannot read, speak, and/or understand English.
Trial population
All patients undergoing an echocardiogram at Tulane Medical Center may be asked to participate in the study.
Trial design
Design model
Other
Time perspective
Cross-sectional
Treatments tested in this trial
Photoplethysmography
Diagnostic testPhotoplethysmography (PPG) is a non-invasive technique that can detect volumetric changes in the peripheral blood. It only requires skin contact and relies on light absorption. PPG is a good indicator of the cardiovascular dynamics in the human body. PPG has been incorporated into various new smartphones and wearable devices such as, smartwatches and fitness wristbands making it readily available to all consumers. This sensor can record biometrics such as, heart rate, blood pressure, oxygen saturation, etc.
Treatment groups
500 Participants
are divided into 1 treatment groupGroup A: Patient Group1 intervention
Trial outcomes
Primary outcomes
1
Association between obtained PPG waveforms and recorded ejection (EF) fractions.
Patients who will undergo echocardiogram will wear the biostrap watch and then the PPG waveform will be obtained. Then, the ejection fraction will be collected from the echocardiogram report. Then, the Artificial Intelligence (AI) staff member will do a predictive model to try and estimate the EF based on the PPG waveform.
Time frame
Day 1Secondary outcomes
1
Association between blood pressure and PPG waveforms
The investigators will record the blood pressure of the patient twice during their visit. Then, the Artificial Intelligence (AI) staff member will do a predictive model to try and estimate the blood pressure based on the PPG waveform.
Time frame
Day1Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov